Phase II trial tests pembrolizumab plus chemotherapy in MSS colorectal cancer — Clinical Colorectal Cancer
A phase II study evaluated pembrolizumab combined with capecitabine and bevacizumab in patients with microsatellite stable/mismatch repair-proficient metastatic colorectal cancer. This trial addresses the challenge that most colorectal cancers (MSS/pMMR) don't respond well to immunotherapy alone.